Navigation Links
Medicago begins human clinical testing with its avian flu pandemic vaccine
Date:10/1/2009

QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has initiated a Phase I human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment is ongoing and vaccination has commenced. The Phase I placebo-controlled, double-blind, dose-escalating study will evaluate safety, tolerability and the immune response of the Company's H5N1 vaccine candidate in 48 healthy volunteers between the ages 18 to 60. Results of this study are expected during the fourth quarter of 2009.

"This first human study with our lead vaccine candidate confirms Medicago's development as a clinical stage company," said Louis P. Vezina, Chief Scientific Officer of Medicago. "This is an important step for our H5N1 vaccine candidate, which has the potential to be highly effective, cross-protective, less expensive and faster to produce than current influenza vaccines."

About Medicago's pandemic flu vaccine candidate

Medicago's H5N1 vaccine candidate was formulated to protect against the avian influenza virus. It is manufactured in Nicotiana benthamiana, a relative of the tobacco plant, using the Company's proprietary VLP technology. VLPs have several advantages over traditional influenza vaccines. They resemble the virus, allowing them to be recognized readily by the body's immune system, however, they lack the core genetic material making them non-infectious and unable to replicate. Medicago's VLP-based vaccine has shown in preclinical studies it can provide cross- protection against different strains of avian flu, such as the Vietnam and Turkey strains. As Medicago's technology requires the genetic sequence of a viral strain and not the live influenza virus, vaccines can be manufactured within 4 weeks of obtaining the genetic sequence ofthe pandemic strain. This is in contrast with all current manufacturing technologies which rely on strain adaptation, leading to an additional 4-6 months before vaccine production can be initiated.

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release

SOURCE Medicago Inc.


'/>"/>
SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
2. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
3. Medicago succesfully expresses VLP antigen for A H1N1 strain
4. Medicago initiates work on Swine Flu strain
5. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
6. Finance Committee Begins Markup - Lab Fee Converted to Medicare Cut
7. America's Organic Home-Fueling Movement Begins in Los Angeles
8. FluMist(R) Begins Shipping for 2009-2010 Influenza Season
9. Mach One Corporation Begins Trading on the OTC Bulletin Board Under the Symbol MNCN
10. Sinovac Begins the Production of Influenza A (H1N1) Vaccine
11. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... CytRx Corporation (NASDAQ: CYTR ), ... today announced the appointment of Earl Warren Brien ... private healthcare investor, to its Board of Directors. ... and strategic experience at the highest level," said ... one of the world,s leading orthopedic surgeons, Dr. Brien ...
(Date:12/2/2016)... ... 01, 2016 , ... Aerocom Healthcare ( http://www.aerocomhealthcare.com ), representing ... its chain-of-custody solution for tracking and securing medications at booth 676 at the ... , Aerocom has a proven solution for tracking medications via its system from ...
(Date:12/2/2016)... ... December 01, 2016 , ... Orthogonal, a Chicago-based medical device ... Class II 510(k) clearance for their flagship medical device, SimplECG. , With this ... devices that rely on cloth-based nanosensors. While other companies have attempted to focus ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
Breaking Biology Technology:
(Date:11/19/2016)... 2016 Securus Technologies, a leading provider of ... investigation, corrections and monitoring, announced today that it has ... have an independent technology judge determine who has the ... tech/sophisticated telephone calling platform, and the best customer service. ... most of what we do – which clearly is ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
Breaking Biology News(10 mins):